Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Hang Tong, Nga V T Phan, Thanh T Nguyen, Dinh V Nguyen, Nam S Vo & Ly Le. (2021) Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions. Pharmacogenomics and Personalized Medicine 14, pages 61-75.
Read now
Read now
Magdalini Migkou, Despina Fotiou, Maria Gavriatopoulou & Meletios Athanasios Dimopoulos. (2021) Ibrutinib plus rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia: a safety evaluation. Expert Opinion on Drug Safety 20:9, pages 987-995.
Read now
Read now
Uffe Klausen, Nicolai Grønne Dahlager Jørgensen, Jacob Handlos Grauslund, Shamaila Munir Ahmad, Anne Ortved Gang, Evelina Martinenaite, Stine Emilie Weis-Banke, Marie Fredslund Breinholt, Guy Wayne Novotny, Julie Westerlin Kjeldsen, Morten Orebo Holmström, Lone Bredo Pedersen, Christian Bjørn Poulsen, Per Boye Hansen, Özcan Met, Inge Marie Svane, Carsten Utoft Niemann, Lars Møller Pedersen & Mads Hald Andersen. (2021) An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma. OncoImmunology 10:1.
Read now
Read now
Gholamreza Azizi, Hassan Abolhassani, Mohammad Hosein Asgardoon, Tina Alinia, Reza Yazdani, Javad Mohammadi, Nima Rezaei, Hans D. Ochs & Asghar Aghamohammadi. (2017) Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management. Expert Review of Clinical Immunology 13:2, pages 101-115.
Read now
Read now
Jan Palmblad, Christer C. Nilsson, Petter Höglund & Helen A. Papadaki. (2016) How we diagnose and treat neutropenia in adults. Expert Review of Hematology 9:5, pages 479-487.
Read now
Read now
David Aguiar-Bujanda, María Jesús Blanco-Sánchez, María Hernández-Sosa, Saray Galván-Ruíz & Samuel Hernández-Sarmiento. (2015) Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. Cancer Management and Research 7, pages 319-330.
Read now
Read now
Yasuyuki Arai, Kouhei Yamashita, Kiyomi Mizugishi, Momoko Nishikori, Masakatsu Hishizawa, Tadakazu Kondo, Toshiyuki Kitano, Hiroshi Kawabata, Norimitsu Kadowaki & Akifumi Takaori-Kondo. (2015) Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. Hematology 20:4, pages 196-202.
Read now
Read now
Qingmin Yao, Xiaojuan Zhu, Yanxia Liu, Feng Zhang, Ting Yuan, Jian Xu & Xin Wang. (2014) Low-dose rituximab in the treatment of acquired haemophilia. Hematology 19:8, pages 483-486.
Read now
Read now
Shawn Shetty & A. R. Ahmed. (2013) Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity 46:8, pages 487-496.
Read now
Read now
Articles from other publishers (51)
Jantien W. Wieringa, Mirjam J. Esser, Jan G.M.C. Damoiseaux, Gertjan A. Driessen & Joyce J.B.C. van Beers. (2023) B cell depletion in infants after intra uterine exposure to immunomodulating chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): A case series and review of the literature. Clinical Immunology Communications 4, pages 1-6.
Crossref
Crossref
E.M. Alba Suárez, A. Tallón Barranco, I. Puertas Muñoz, B. Chamorro Hernández & Á. Robles Marhuenda. (2023) Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab. Neurología (English Edition) 38:7, pages 463-466.
Crossref
Crossref
E.M. Alba Suárez, A. Tallón Barranco, I. Puertas Muñoz, B. Chamorro Hernández & Á. Robles Marhuenda. (2023) Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab. Neurología 38:7, pages 463-466.
Crossref
Crossref
Tejas S. Athni & Sara Barmettler. (2023) Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Annals of Allergy, Asthma & Immunology 130:6, pages 699-712.
Crossref
Crossref
Jérôme de Sèze, Elisabeth Maillart, Antoine Gueguen, David A. Laplaud, Laure Michel, Eric Thouvenot, Hélène Zephir, Luc Zimmer, Damien Biotti & Roland Liblau. (2023) Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Frontiers in Immunology 14.
Crossref
Crossref
Jakob Rishovd Karlowicz, Mattias Klakegg, Jan Harald Aarseth, Lars Bø, Kjell-Morten Myhr, Hilde Marie Torgauten, Øivind Torkildsen & Stig Wergeland. (2023) Predictors of hospitalization due to infection in rituximab-treated MS patients. Multiple Sclerosis and Related Disorders 71, pages 104556.
Crossref
Crossref
Annaliesse Blincoe, Roxane Labrosse & Roshini S. Abraham. (2022) Acquired B-cell deficiency secondary to B-cell-depleting therapies. Journal of Immunological Methods 511, pages 113385.
Crossref
Crossref
Mai Alalawi, Abrar Saeed Bakr, Rowaida Reda, Karim Thomas Sadak & Mohamad Nagy. (2022) Late-onset toxicities of monoclonal antibodies in cancer patients. Immunotherapy 14:13, pages 1067-1083.
Crossref
Crossref
Naman Sharma, Patrick M. Reagan & Jane L. Liesveld. (2022) Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem. Cancers 14:6, pages 1501.
Crossref
Crossref
Ramon Diez-Feijóo, Juan Jose Rodríguez-Sevilla, Concepcion Fernández-Rodríguez, Solange Flores, Carmen Raya, Ana Ferrer, Luis Colomo & Antonio Salar. (2022) Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine. Frontiers in Immunology 12.
Crossref
Crossref
Chaithanya Reddy, Chandana Bhagwat & ArushiGahlot Saini. (2022) Immunotherapies in pediatric neurology during the COVID-19 pandemic: A pragmatic approach. Journal of Pediatric Neurosciences 17:1, pages 12.
Crossref
Crossref
Christen Sheng Jie Lim, Janis Siew Noi Tye, Kevin Tan & Tianrong Yeo. (2022) Late-onset neutropenia following anti-CD20 therapies in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: A report on two patients. Neuroimmunology Reports 2, pages 100136.
Crossref
Crossref
Clara Grazia Chisari, Eleonora Sgarlata, Sebastiano Arena, Simona Toscano, Maria Luca & Francesco Patti. (2021) Rituximab for the treatment of multiple sclerosis: a review. Journal of Neurology 269:1, pages 159-183.
Crossref
Crossref
William PH Kermode, Simon Kavanagh & Allan G Kermode. (2021) Myeloid maturation arrest and severe late-onset neutropenia following ocrelizumab therapy in a patient with multiple sclerosis: A case report and review of the literature. Neuroimmunology Reports 1, pages 100012.
Crossref
Crossref
Mariano Marrodan, Julia Laviano, Sofía Oneto, Fabricio M. Reino, Ricardo Delorme, Florencia Fornillo, José Férnandez & Jorge Correale. (2021) Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient. Neurological Sciences 42:9, pages 3893-3895.
Crossref
Crossref
Nabil Seery, Sifat Sharmin, Vivien Li, Ai-Lan Nguyen, Claire Meaton, Roberts Atvars, Nicola Taylor, Kelsey Tunnell, John Carey, Mark P. Marriott, Katherine A. Buzzard, Izanne Roos, Chris Dwyer, Josephine Baker, Lisa Taylor, Kymble Spriggs, Trevor J. Kilpatrick, Tomas Kalincik & Mastura Monif. (2021) Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study. CNS Drugs 35:8, pages 907-918.
Crossref
Crossref
Daniel Tesfa, Birgitta Sander, Henric Lindkvist, Christer Nilsson, Eva Kimby, Hans Hägglund, Björn E. Wahlin, Monika Klimkowska & Jan Palmblad. (2021) The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas. Medical Oncology 38:6.
Crossref
Crossref
Rebecca Clark, Diana Lindsey, Susan Whiteway, Cecilia Mikita & Kenneth Lieuw. (2021) Dysfunctional Immune System Reconstitution After Rituximab Exposure In Utero. Journal of Pediatric Hematology/Oncology 43:4, pages e601-e604.
Crossref
Crossref
F. Gascon-Gimenez, A. Teruel-Casasus, J.A. Domínguez-Morán & J.M. Láinez. (2021) Neutropenia tóxica tras ocrelizumab sin recurrencias posteriores tras continuar el tratamiento. Neurology Perspectives 1:2, pages 143-145.
Crossref
Crossref
Reza Zonozi, Zachary S. Wallace, Karen Laliberte, Noah R. Huizenga, Jillian M. Rosenthal, Eugene P. Rhee, Frank B. Cortazar & John L. Niles. (2020) Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease. Arthritis & Rheumatology 73:2, pages 347-354.
Crossref
Crossref
Michael Auer, Gabriel Bsteh, Harald Hegen, Sebastian Wurth, Anne Zinganell, Thomas Berger, Florian Deisenhammer & Franziska Di Pauli. (2020) Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. Multiple Sclerosis and Related Disorders 43, pages 102155.
Crossref
Crossref
Marc Pawlitzki, Uwe K. Zettl, Tobias Ruck, Leoni Rolfes, Hans-Peter Hartung & Sven G. Meuth. (2020) Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-PandemieRisks and possibilities of immunotherapy in times of the coronavirus 2019 pandemic. DGNeurologie 3:4, pages 285-297.
Crossref
Crossref
J. Rigal, J. Ciron, Z. Lépine & D. Biotti. (2020) Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases. Multiple Sclerosis and Related Disorders 41, pages 102019.
Crossref
Crossref
Marc Pawlitzki, Uwe K. Zettl, Tobias Ruck, Leoni Rolfes, Hans-Peter Hartung & Sven G. Meuth. (2020) Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. EBioMedicine 56, pages 102822.
Crossref
Crossref
Konstantin Dobrenkov & Nai-Kong V. Cheung. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
486
499.e8
.
Mayuko Yamazaki, Hidekazu Sugiura, Yosuke Iwatani, Mizuki Kyoda, Hirohiko Nokiba, Nobuyuki Amemiya, Kosaku Nitta & Ken Tsuchiya. (2019) Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome. Case Reports in Nephrology 2019, pages 1-4.
Crossref
Crossref
Seza Ozen & Saliha Esenboga. 2019. Cytokine Storm Syndrome. Cytokine Storm Syndrome
581
593
.
Jürgen Barth. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
489
519
.
Sandra LockmerBjørn ØstenstadHans HagbergHarald HolteAnn-Sofie JohanssonBjörn Engelbrekt WahlinKarin Fahl WaderChloé Beate SteenPeter MeyerMartin MaisenhølderKarin Ekström SmedbyPeter BrownEva Kimby. (2018) Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. Journal of Clinical Oncology 36:33, pages 3315-3323.
Crossref
Crossref
Damien Biotti, Fleur Lerebours, Fabrice Bonneville, Jonathan Ciron, Michel Clanet & David Brassat. (2018) Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder. Multiple Sclerosis Journal 24:12, pages 1645-1647.
Crossref
Crossref
I Parodis, F Söder, F Faustini, Z Kasza, I Samuelsson, A Zickert, E Svenungsson, R F van Vollenhoven, V Malmström, F Wermeling & I Gunnarsson. (2018) Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL. Lupus 27:9, pages 1470-1478.
Crossref
Crossref
Muhammad Abdul Mabood Khalil, Muhammad Ashhad Ullah Khalil, Taqi F. Taufeeq Khan & Jackson Tan. (2018) Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians. Journal of Transplantation 2018, pages 1-22.
Crossref
Crossref
Catherine King, Lorraine Harper & Mark Little. (2018) The complications of vasculitis and its treatment. Best Practice & Research Clinical Rheumatology 32:1, pages 125-136.
Crossref
Crossref
L. K. Schoch, A. Asiama, M. Zahurak, S. Shanbhag, J. Hurtt, K. Sawyer, L. J. Swinnen, N. Wagner-Johnston, R. J. Jones, R. F. Ambinder & Douglas E. Gladstone. (2017) Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients. Cancer Chemotherapy and Pharmacology 81:2, pages 347-354.
Crossref
Crossref
B. Verriere, L. Gastaud, E. Chamorey, F. Peyrade, E. Deletie, K. Bouredji, D. Quinsat, R. Schiappa, A. Thyss & D. Re. (2018) Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab. Hematological Oncology 36:1, pages 144-149.
Crossref
Crossref
Sofia Ajeganova, Daniel Tesfa, Hans Hägglund, Bengt Fadeel, Inger Vedin, Anna Linda Zignego & Jan Palmblad. (2017) Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab. Arthritis Research & Therapy 19:1.
Crossref
Crossref
William E. Monaco, Jonathan D. Jones & William F.C. Rigby. (2016) Rituximab associated late-onset neutropenia—a rheumatology case series and review of the literature. Clinical Rheumatology 35:10, pages 2457-2462.
Crossref
Crossref
Efstathios Kastritis & Meletios A. Dimopoulos. (2016) Current therapy guidelines for Waldenstrom's macroglobulinaemia. Best Practice & Research Clinical Haematology 29:2, pages 194-205.
Crossref
Crossref
Marco A. Alba & Luis Felipe Flores-Suárez. (2016) Rituximab as Maintenance Therapy for ANCA Associated Vasculitis: How, When and Why?. Reumatología Clínica (English Edition) 12:1, pages 39-46.
Crossref
Crossref
Marco A. Alba & Luis Felipe Flores-Suárez. (2016) Rituximab como terapia de mantenimiento en las vasculitis asociadas a ANCA: ¿cómo, cuándo y por qué?. Reumatología Clínica 12:1, pages 39-46.
Crossref
Crossref
Md Yuzaiful Md Yusof, Edward M. Vital & Maya H. Buch. (2015) B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. Current Rheumatology Reports 17:10.
Crossref
Crossref
Rachel B. Jones. (2014) Rituximab in the Treatment of Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis. Nephron Clinical Practice 128:3-4, pages 243-249.
Crossref
Crossref
Nai-Kong V. Cheung. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
508
518.e7
.
M. Kasahara, K. Umeshita, Y. Inomata & S. Uemoto. (2013) Long-Term Outcomes of Pediatric Living Donor Liver Transplantation in Japan: An Analysis of More Than 2200 Cases Listed in the Registry of the Japanese Liver Transplantation Society. American Journal of Transplantation 13:7, pages 1830-1839.
Crossref
Crossref
Jack Uetrecht & Dean J. Naisbitt. (2013) Idiosyncratic Adverse Drug Reactions: Current Concepts. Pharmacological Reviews 65:2, pages 779-808.
Crossref
Crossref
Paul R. Burchard, Saurabh Malhotra, Prabhjot Kaur & Gregory J. Tsongalis. (2013) Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay. Cancer Genetics 206:4, pages 130-134.
Crossref
Crossref
Hideki Ishida, Masashi Inui, Miyuki Furusawa & Kazunari Tanabe. (2013) Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation — Single-center study. Transplant Immunology 28:2-3, pages 93-99.
Crossref
Crossref
Nancy E. Everds & Jacqueline M. Tarrant. (2013) Unexpected Hematologic Effects of Biotherapeutics in Nonclinical Species and in Humans. Toxicologic Pathology 41:2, pages 280-302.
Crossref
Crossref
Laurence A. Boxer. (2012) How to approach neutropenia. Hematology 2012:1, pages 174-182.
Crossref
Crossref
Nadezhda Wall & Lorraine Harper. (2012) Complications of long-term therapy for ANCA-associated systemic vasculitis. Nature Reviews Nephrology 8:9, pages 523-532.
Crossref
Crossref
Charles S. Cleeland, Jeff D. Allen, Samantha A. Roberts, Joanna M. Brell, Sergio A. Giralt, Aarif Y. Khakoo, Rebecca A. Kirch, Virginia E. Kwitkowski, Zhongxing Liao & Jamey Skillings. (2012) Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nature Reviews Clinical Oncology 9:8, pages 471-478.
Crossref
Crossref